A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- BMC INFECTIOUS DISEASES23(1) · 2023
- 피인용
- Web of Science 2Scopus 4
- FWCI (Scopus)
- 0.43
- JCR IF
- JCR 2022 3.7
- ISSN
- 1471-2334
저자
- Shim, Tae Sun제1저자Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
- Pai, Helen교신저자Janssen Res & Dev LLC, Raritan, NJ 08869 USA
- 목정하Pusan Natl Univ Hosp, Busan, South Korea
- Lee, Seung HeonKorea Univ, Ansan Hosp, Ansan, South Korea
- Kwon, Yong-SooChonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Gwangju, South Korea
- Choi, Jae CholChung Ang Univ Hosp, Seoul, South Korea
- Park, JaeSeokDankook Univ Hosp, Cheonan, South Korea
- Birmingham, EileenJanssen Res & Dev LLC, Raritan, NJ 08869 USA
- Mao, GaryJanssen Res & Dev LLC, Raritan, NJ 08869 USA
- Alquier, LoriJanssen Res & Dev LLC, Raritan, NJ 08869 USA
- Davis, KourtneyJanssen Res & Dev LLC, Raritan, NJ 08869 USA
- Thoret-Bauchet, FlorenceJanssen Cilag, Issy Les Moulineaux, France
- Kim, Ji HyunJanssen Korea, Seoul, South Korea
- Kim, HyeongyeongJanssen Korea, Seoul, South Korea
- Bakare, NyashaJanssen Res & Dev LLC, Raritan, NJ 08869 USA
초록
© 2022, The Author(s).Background: Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB. Methods: A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen. Treatment was at the physician’s discretion (bedaquiline use requiring approval by special committee) and was based on patient characteristics, disease status, and local treatment guidelines. Results: The safety population included 172 patients (88 bedaquiline and 84 non-bedaquiline). The mean (standard deviation, SD) duration of follow-up was 24.3 (9.5) months. Mean (SD) durations of treatment were 5.4 (1.8) months in bedaquiline-treated patients and 15.7 (6.7) months in the non-bedaquiline group. Treatment success (cured and treatment completed according to WHO 2013 treatment outcome definitions) was achieved by 56.3% of bedaquiline-treated and 45.2% of non-bedaquiline-treated patients. Sputum culture conversion rates were 90.4% and 83.7% with and without bedaquiline, respectively. Diarrhoea and nausea were the most frequently reported treatment-emergent adverse events (TEAEs) in the bedaquiline group (27.3% [24/88] and 22.7% [20/88], respectively). The most frequent bedaquiline-related TEAEs were prolonged QT interval (10.2%; 9/88), and diarrhoea and nausea (9.1% each; 8/88). QT interval prolongation was reported in 19.3% (17/88) of bedaquiline-treated and 2.4% (2/84) of non-bedaquiline-treated patients, but bedaquiline was not discontinued for any patient for this reason. There were 13 (14.7%) and three (3.6%) deaths in the bedaquiline-treated and non-bedaquiline groups, respectively. Review of fatal cases revealed no unexpected safety findings, and no deaths were bedaquiline-related. The most common cause of death was worsening cancer (three patients). Patients in the bedaquiline group tended to have poorer baseline risk profiles than non-bedaquiline patients and were more likely to have relapsed or already failed second-line treatment. Interpretation of mortality data was complicated by high rates of loss to follow-up in both groups. Conclusions: The South Korean registry findings support previous risk/benefit observations and the continued use of bedaquiline as part of combination therapy in patients with MDR-TB.
키워드
BedaquilineMultidrug-resistantSouth KoreaTuberculosisOUTCOMESTMC207
식별자
- Scopus EID
- 2-s2.0-85145956690
- WoS UID
- 000911337300004



로그인
연구물 목록으로